Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma by Jamin, Yann et al.
 
Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Jamin, Yann, Laura Glass, Albert Hallsworth, Rani George, Dow-
Mu Koh, Andrew D. J. Pearson, Louis Chesler, and Simon P.
Robinson. 2014. “Intrinsic Susceptibility MRI Identifies Tumors
with ALKF1174L Mutation in Genetically-Engineered Murine




Accessed February 19, 2015 3:45:17 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064501
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAIntrinsic Susceptibility MRI Identifies Tumors with
ALK
F1174L Mutation in Genetically-Engineered Murine






1, Andrew D. J. Pearson
4,
Louis Chesler
1,2,3,4, Simon P. Robinson
1
1Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom, 2Division of Cancer
Therapeutics, The Institute of Cancer Research, London, United Kingdom, 3Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom,
4Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom, 5Department of Pediatric Haematology and Oncology, Dana-Farber Cancer
Institute and Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
The early identification of children presenting ALK
F1174L-mutated neuroblastoma, which are associated with resistance to the
promising ALK inhibitor crizotinib and a marked poorer prognosis, has become a clinical priority. In comparing the radiology
of the novel Th-ALK
F1174L/Th-MYCN and the well-established Th-MYCN genetically-engineered murine models of
neuroblastoma using MRI, we have identified a marked ALK
F1174L-driven vascular phenotype. We demonstrate that
quantitation of the transverse relaxation rate R2*( s
21) using intrinsic susceptibility-MRI under baseline conditions and
during hyperoxia, can robustly discriminate this differential vascular phenotype, and identify MYCN-driven tumors harboring
the ALK
F1174L mutation with high specificity and selectivity. Intrinsic susceptibility-MRI could thus potentially provide a non-
invasive and clinically-exploitable method to help identifying children with MYCN-driven neuroblastoma harboring the
ALK
F1174L mutation at the time of diagnosis.
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Neuroblastoma arises in the sympathetic nervous system during
embryogenesis and is the most common extracranial solid tumor
in children [1]. For the established subset of patients presenting
with high-risk neuroblastoma, the current portfolio of therapeutic
options has limited success, with five-year survival rates rarely
exceeding 40%.
The poor clinical outcome and aggressive tumor phenotype of
high-risk neuroblastoma strongly correlates with amplification of
the proto-oncogene MYCN and enhanced tumor angiogenesis [2].
Recently, mutations in the anaplastic lymphoma kinase (ALK)
tyrosine kinase gene have been identified in ,8–10% of primary
neuroblastoma, leading to constitutive activation of the ALK
protein. The most common and potent ALK mutation, ALK
F1174L,
is associated preferentially with MYCN amplification, a markedly
poorer prognosis, and confers resistance to the promising ALK
inhibitor crizotinib [3–5].
With crizotinib in pediatric phase I clinical trials, and other ALK
inhibitor studies in development, a current challenge is to rapidly
identify upfront children with high-risk ALK mutated or amplified
neuroblastoma who may benefit from or become resistant to ALK-
targeted therapy.
As most pediatric cancers, including neuroblastoma, originate
from only a few genetic anomalies during development, they are
amenable to genetically engineered mouse (GEM) modeling
approaches. GEM models of neuroblastoma, such as the Th-
MYCN murine model, which develop spontaneous tumors
mirroring the major pathophysiological, genetic and radiological
features of high-risk MYCN-amplified childhood neuroblastoma,
represent clinically-relevant tools for the study of neuroblastoma
biology and response to novel therapeutics [6–8]. The develop-
ment of GEM models co-expressing ALK
F1174L and MYCN to the
neural crest, such as the Th-ALK
F1174L/Th-MYCN model, have
recently been used to demonstrate how the ALK
F1174L mutation
potentiates the oncogenic activity of MYCN, and that ALK
F1174L
acquired resistance to crizotinib can be overcome through
inhibition of key cellular modulators of n-myc [9–11].
In this study, we hypothesized that the presence of the
ALK
F1174L mutation results in a phenotypic difference in hemo-
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e92886dynamic vasculature in tumors in the Th-ALK
F1174L/Th-MYCN
model, and which can be evaluated using intrinsic susceptibility
magnetic resonance imaging (MRI). The aim of our study was to
demonstrate that quantitation of the transverse relaxation rate,
R2*, and changes in R2* induced by breathing 100% oxygen,
DR2*oxygen-air, could discriminate between tumors arising in Th-
ALK
F1174L/Th-MYCN and Th-MYCN mice, and that intrinsic
susceptibility MRI could thus potentially provide a non-invasive
and clinically-translatable method to help identify children,





All procedures involving animals were approved by the Institute
of Cancer Research Animal Ethics Committee and the UK Home
Office and carried out according to the United Kingdom National
Cancer Research Institute guidelines for the welfare of animals in
cancer research [12].
Animal models
The generation of the Th-ALK
F1174L/Th-MYCN mice has been
recently described [11]. Th-ALK
F1174L/Th-MYCN and Th-MYCN
mice were identified by analyzing DNA from mice tails using real-
time quantitative reverse transcription polymerase chain reaction
(qRT-PCR, Transnetyx Inc., Cordova, Tennessee), and mice with
tumors were initially identified by palpation.
Magnetic Resonance Imaging
All the
1H MRI studies were performed on a 7T Bruker
horizontal bore micro-imaging system (Bruker Instruments,
Ettlingen, Germany) using a 3 cm birdcage coil. Anesthesia was
induced by an intraperitoneal 0.1 ml injection of a combination of
fentanyl citrate (0.315 mg/ml) plus fluanisone (10 mg/ml) (Hyp-
norm, Janssen Pharmaceutical, Oxford, UK) and midazolam
(5 mg/ml) (Roche, Welwyn Garden City, UK) and water (1:1:2).
A nose piece was positioned for oxygen delivery.
For all the mice, anatomical T2-weighted coronal and
transverse images were acquired from twenty contiguous 1 mm-
thick slices through the mouse abdomen, using a rapid acquisition
with refocused echoes (RARE) sequence with 4 averages of 128
phase encoding steps over a 363 cm field of view, two echo times
(TE) of 36 and 132 ms, a repetition time (TR) of 4.5 s and a
RARE factor of 8. These images were used to determine tumor
volumes, and for planning the intrinsic-susceptibility MRI
measurements, which included optimization of the local field
homogeneity. The baseline transverse relaxation rate R2*,
sensitive to the concentration of paramagnetic species, principally
deoxyhemoglobin, was quantified in tumors from Th-ALK
F1174L/
Th-MYCN (n=23) and Th-MYCN (n=21) mice, using a multiple
gradient echo (MGE) sequence. MGE images were acquired from
three 1 mm thick transverse slices through each tumor, using 8
averages of 128 phase encoding steps over a 363 cm field of view,
and an acquisition time of 3 min 20 s. Images were acquired using
8 echoes spaced 3 ms apart, an initial echo time of 6 ms, a flip
angle a=45u and a repetition time of 200 ms. Subsequently,
100% oxygen (BOC Ltd, Guildford, UK) was delivered at a rate of
2 L/min to Th-ALK
F1174L/Th-MYCN (n=10) and Th-MYCN
(n=12) mice. After a 5 minutes equilibrium period, identical
MGE images were acquired whilst the mouse continued to inhale
oxygen.
All the MGE data were fitted voxelwise using in-house software
(ImageView, working under IDL, ITT, Boulder, Colorado, USA)
with a robust Bayesian approach that provided estimates of R2*
and DR2*oxygen-air (=R 2*oxygen2R2*air) [13].
Histological Assessment
Formalin fixed paraffin embedded sections from Th-ALK
F1174L/
Th-MYCN and Th-MYCN mice were stained with haematoxylin
and eosin, and visualized under light microscopy. The extent of
functional vasculature in tumors from both models was assessed
using the perfusion marker Hoechst 33342, and quantified as
fluorescent area fractions (%), as previously described [8].
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
(GraphPad Software Inc., La Jolla, USA). The mean values for
tumor volume, mean of median values for R2* and DR2*oxygen-air,
and the mean fluorescent area fractions were used for statistical
analysis. R2* and DR2*oxygen-air were assumed to be normally
distributed, which was confirmed using the D’Agostino-Pearson
omnibus K
2 normality test [14]. Any significant difference in
tumor volume, R2*, DR2*oxygen-air and the fluorescent area
fractions between Th-ALK
F1174L/Th-MYCN and Th-MYCN mice




F1174Lmutation induces a differential radiological
presentation of neuroblastoma
Anatomical T2-weighted RARE MR images revealed solid
masses within the retroperitoneum in peri-renal and para-spinal
abdominal regions of both the Th-ALK
F1174L/Th-MYCN and Th-
MYCN mice, typical of the clinical distribution and radiological
presentation of human neuroblastoma (Figure 1A) [15,16]. All the
Th-ALK
F1174L/Th-MYCN (n=23) and Th-MYCN (n=21) mice
examined presented with abdominal tumors with wide range of
volumes (525–3400 mm
3 for tumors in Th-ALK
F1174L/Th-MYCN
mice and 335–2450 mm
3 for tumors in Th-MYCN mice). Tumors
in the Th-MYCN mice appeared heterogeneous, with 94% of
tumors presenting with areas of hypointense signal, consistent with
previous observations [8]. Tumors in the Th-ALK
F1174L/Th-
MYCN mice were generally hyperintense and significantly more
homogeneous, with only 48% of the tumors having hypointense
regions (p=0.006, x
2-test). On T2*-weighted images (Figure 1B
and C, and Figure 2A), tumors in the Th-MYCN mice were
generally hypointense at longer echo times, whereas the signal
from tumors in the Th-ALK
F1174L/Th-MYCN remained hyperin-
tense, providing a stark positive contrast with the surrounding
organs for 74% of the Th-ALK
F1174L/Th-MYCN mice (compared
to 14% for the Th-MYCN mice, p,0.001, x
2-test).
ALK
F1174Lmutation results in a slower tumor transverse
relaxation rate, R2
*, in neuroblastoma
Parametric maps revealed a heterogeneous distribution of R2*
in tumors in both models (Figure 2B). Quantitation of the
transverse relaxation R2* revealed significantly slower rates in
tumors in the Th-ALK
F1174L/Th-MYCN cohort, compared to the
faster R2* rate determined in tumors in the Th-MYCN mice
(Figure 2D). Baseline R2* detected tumors harboring the
ALK
F1174L mutation with a sensitivity of 90% (95% CI: 66.9–
98.2) and a specificity of 81% (95% CI: 57.4–93.7).
Identifying ALK-Mutated Neuroblastoma with MRI
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F1174Lmutation is associated with a stark differential
BOLD MRI response to hyperoxic challenge in
neuroblastoma
Continuous inhalation of 100% oxygen resulted in tumors in the
Th-MYCN mice demonstrating a very strong, heterogeneous
increase in T2*-weighted image signal intensity (blood oxygen
level dependent (BOLD) effect) (Figure 2A). In contrast, tumors
from Th-ALK
F1174L/Th-MYCN mice showed a negligible BOLD
effect on T2* weighted image intensity with hyperoxia. As with
baseline R2*, parametric maps revealed a heterogeneous distribu-
tion of DR2*oxygen-air in tumors in both models (Figure 2B and C).
Tumor regions showing a relatively fast baseline R2* remained so
during hyperoxia, whereas regions of relatively slower baseline R2*
typically showed a more marked reduction in R2* with 100% O2.
The significant difference in R2* between the two models was lost
with 100% oxygen challenge (Figure 2E). As a consequence,
tumors in Th-ALK
F1174L/Th-MYCN mice demonstrated a signif-
icantly lower absolute value of DR2*oxygen-air than the tumors in
Th-MYCN mice (Figure 2F). Hyperoxia-induced DR2*oxygen-air
detected tumors harboring the ALK
F1174L mutation with a
sensitivity of 90% (95% CI: 54.1–99.5) and a specificity of
94.1% (95% CI: 69.2–99.7).
Figure 1. Radiological comparison of the Th-ALK
F1174L/Th-MYCN and Th-MYCN mice with abdominal neuroblastoma. A) Anatomical
transverse T2-weighted MR images acquired with a rapid acquisition with refocused echoes (RARE) sequence and B) anatomical transverse T2*-
weighted MR images acquired at increasing gradient echo times as indicated, from representative presenting with abdominal neuroblastoma. C)




Figure 2. Identification of tumors harboring the ALK
F1174L mutation in MYCN-driven transgenic mice with intrinsic susceptibility MRI.
A) Anatomical transverse T2*-weighted MR images acquired at TE=6.8 and 15.6 ms from representative Th-ALK
F1174L/Th-MYCN and Th-MYCN mice
with abdominal neuroblastoma during initial air breathing, and at TE=15.6 ms after 5 minutes of continuous inhalation of 100% oxygen. B)
Corresponding parametric tumor transverse relaxation rate R2* maps calculated during initial air breathing and after 3 minutes of continuous
inhalation of 100% oxygen. C) Resulting parametric tumor DR2*oxygen-air (R2*oxygen2R2*air) maps. D) Tumor R2* during initial air breathing, E) tumor
R2* after 5 minutes of breathing 100% oxygen, and F) tumor DR2*oxygen-air (R2*oxygen2R2*air) were determined from Th-ALK
F1174L/Th-MYCN and Th-
MYCN mice with abdominal neuroblastoma. Individual data points represent the mean of the median values determined from all three imaging slices
for each animal, as well as the mean 61 s.e.m, p, Student’s 2-tailed unpaired t-test with a 5% level of significance.
doi:10.1371/journal.pone.0092886.g002
Identifying ALK-Mutated Neuroblastoma with MRI
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between either R2*o rDR2*oxygen-air and tumor volume, was
determined across the cohorts, indicating that the differences in
intrinsic susceptibility MRI between tumors in the Th-ALK
F1174L/
Th-MYCN and Th-MYCN mice were independent of tumor size.
ALK
F1174Lmutation is associated with reduced functional
vasculature in neuroblastoma
Gross examination of the tumors in situ, prior to excision,
revealed an intense dark red coloration across the whole tumor in
the Th-MYCN mice, in contrast to the pale appearance of tumors
in the Th-ALK
F1174L/Th-MYCN GEM model (Figure 3A). Histo-
logical examination with H&E staining revealed the presence of
large hemorrhagic regions filled with stacked erythrocytes in 100%
of the tumors from Th-MYCN mice (n=10), but only in 10% the
Th-ALK
F1174L/Th-MYCN model (n=10, p,0.0001, x
2-test)
(Figure 3B and C). Fluorescence microscopy of Hoechst 33342
uptake revealed homogeneously and well-vascularized tumors in
both models (Figure 3D). However, quantitation of the fluorescent
area fractions revealed that tumors in the Th-MYCN mice had
significantly higher uptake, consistent with the presence of more
perfused, functional vasculature (Figure 3E).
Discussion
In the current study we demonstrate that baseline R2* and
hyperoxia-induced DR2* can discriminate a differential hemody-
namic tumor vascular phenotype between tumors arising in Th-
ALK
F1174L/Th-MYCN and Th-MYCN models of high-risk, MYCN
over-expressing neuroblastoma. With a sensitivity of 90% and a
specificity of 81% for baseline R2*, and a sensitivity of 90% and a
specificity of 94% for 100% oxygen-induced DR2*, intrinsic
susceptibility MRI provides a robust method to discriminate and
identify Th-MYCN transgenic mice harboring the ALK
F1174L
mutation.
The rapid and completely noninvasive quantitation of tumor
R2* is suitable for the scanning of young children. Furthermore,
such pediatric imaging sessions are usually performed under
general anesthesia, providing an opportunity to transiently perturb
the oxygen content inhaled by the patient, and enabling
quantitation of tumor R2* under more hyperoxic conditions (from
21 to 30–40% O2). Upon successful translation, intrinsic
susceptibility MRI could provide a rapid method to identify
children with ALK-driven tumors, enabling the stratification of
children with this ultra high-risk neuroblastoma at the time of
diagnosis.
The baseline transverse relaxation rate R2* is sensitive to the
concentration of paramagnetic deoxyhemoglobin in the vascular
compartment in tissue (BOLD effect). Compared to most normal
tissues, tumors exhibit relatively fast native R2* values, a
consequence of the high concentration of deoxygenated erythro-
cytes within the vascular compartment associated with immature,
irregular and unstable microcirculation [17]. The fast baseline
tumor R2* measured in the Th-MYCN model is consistent with the
aggregation of deoxygenated erythrocytes, described as blood lakes
[18], and which are characteristic of childhood neuroblastoma
[19]. The significantly slower baseline R2* and differential intrinsic
susceptibility MRI presentation of tumors in the Th-ALK
F1174L/
Th-MYCN mice is consistent with the absence of such blood lakes.
Inhalation of high oxygen content gases results in the rapid re-
oxygenation of hemoglobin, with paramagnetic deoxyhemoglobin
within perfused tumor vessels being replaced by diamagnetic
oxyhemoglobin, and a reduction in R2* [20]. Hyperoxia resulted
in an overall significant reduction in R2* of tumors in the Th-
MYCN mice, whereas the response in tumors in the Th-ALK
F1174L/
Th-MYCN mice was negligible, suggesting a clear difference in
hemodynamic functional vasculature between the two GEM
models. This was corroborated by the significant overall difference
in Hoechst 33342 uptake. Interestingly, a spatially different
hyperoxia DR2* response was apparent in tumors in the Th-
MYCN mice. Tumor regions exhibiting relatively fast baseline R2*
showed a less pronounced response with 100% O2 breathing, also
consistent with the presence of blood lakes which are typically
disconnected from the perfused vascular network [21]. In contrast,
tumor regions with relatively slower baseline R2* showed a
marked response to hyperoxia, indicative of functional vasculature.
Intriguingly, tumors from the Th-ALK
F1174L/Th-MYCN mice
showed no clear DR2* response to hyperoxia, despite Hoechst
Figure 3. Pathological comparison of tumors from Th-ALK
F1174L/Th-MYCN and Th-MYCN mice with abdominal neuroblastoma. A)
Gross pathology, B) composite images, and C) high magnification (x200) images from hematoxylin and eosin stained sections. Note the presence of
large hemorrhagic regions filled with aggregated erythrocytes (*, blood lakes) extravasated from blood vessels (arrowed) in the tumor from the Th-
MYCN mouse. D) Composite fluorescence images of uptake of the perfusion marker Hoechst 33342 into tumors from Th-ALK
F1174L/Th-MYCN and Th-
MYCN mice with abdominal neuroblastoma. E) Quantitation of Hoechst 33342 uptake revealed significantly lower functionally perfused vasculature in
tumors of Th-ALK
F1174L/Th-MYCN mice (n=5) compared with tumors in Th-MYCN mice (n=5). Data are mean 61 s.e.m, p, Student’s 2-tailed unpaired
t-test with a 5% level of significance.
doi:10.1371/journal.pone.0092886.g003
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both GEM models. This suggests a difference in vascular
architecture that precludes erythrocyte delivery, but not plasma
perfusion, in the tumor vessels in the Th-ALK
F1174L/Th-MYCN
mice, or in oxygen consumption by the tumor cells [17,22]. The
extensive hemorrhage and blood lakes present in the Th-MYCN
model are indicative of vessel wall instability due to rapid
endothelial cell proliferation and defective pericyte coverage
[23]. This implies that the tumor vasculature in the Th-
ALK
F1174L/Th-MYCN mice may be more mature.
Given its relationship to blood oxygen saturation and partial
pressure of oxygen in and around blood vessels, quantitation of
baseline tumor R2* is also being investigated as an imaging
biomarker of hypoxia [24]. For example, slow baseline R2* has
been shown to correlate with increased hypoxia, determined by
pimonidazole staining, in chemically-induced rat mammary
tumors [25]. Conversely, fast baseline R2* is associated with
hypoxia in prostate cancer [26]. In this context, we have recently
shown that neuroblastoma from Th-MYCN mice exhibiting fast
baseline R2*, induced by a hemorrhagic phenotype, are relatively
oxic, as revealed by negligible pimonidazole staining [8]. R2*i s
first of all a marker of impaired hemodynamic function and as
such shares a causal relationship to hypoxia. However this
relationship is ambivalent as several differential hemodynamic
phenotypes can in fact lead to hypoxia, while having an opposite
effect on R2* values. In this study the suggested tumor vascular
phenotype in the Th-ALK
F1174L/Th-MYCN model, which hinders
the delivery of erythrocytes and causes a significantly slower R2*,
may result in increased tumour hypoxia in the Th-ALK
F1174L/Th-
MYCN model compared with the Th-MYCN model.
Recent reports have implicated a role of the ALK
F1174L mutation
in tumor angiogenesis in neuroblastoma. Selective targeted
inhibition of ALK resulted in a significant reduction in vascular
density in xenografts derived from MYCN non-amplified SH-
SY5Y cells, which harbor the ALK
F1174L mutation, accompanied
with a decrease in vascular endothelial growth factor (VEGF) and
matrix metalloproteinases (MMPs) [27]. The expression of MMP-
9 by stromal cells has previously been shown to regulate the
vascular architecture in a murine orthotopic MYCN-amplified
neuroblastoma xenograft model by promoting pericyte recruit-
ment [28]. Collectively, these studies suggest that ALK and the
ALK
F1174L mutation contribute to tumor vasculogenesis and
pericyte recruitment via the regulation of VEGF and MMP-9,
leading to a dense vascular network with smaller, more stable
vessels. The differential intrinsic susceptibility MRI vascular
phenotype observed in tumors in the Th-MYCN and Th-
ALK
F1174L/Th-MYCN models reported herein demonstrates an
important role for ALK
F1174L in angiogenesis in MYCN-overex-
pressing neuroblastoma in vivo, strongly suggesting a role in
vasculogenesis.
This study has some limitations. The Th-ALK
F1174L mutation
leads to the constitutive activation of the ALK protein in
neuroblastoma [29–32], and the vascular phenotype associated
with amplified or wild-type (WT) ALK expression is currently
unknown. Amplification of ALK has also been shown to lead to
activation of the ALK protein with, however, a 17-fold reduced
kinase activity compared to ALK
F1174L mutants [29]. In the
absence of a Th-ALK
wt GEM model, it is difficult to conclude if
intrinsic susceptibility MRI would be solely able to identify
ALK
F1174L-mutated MYCN amplified neuroblastoma, or more
generally ALK-driven MYCN amplified neuroblastoma.
There is a clear need to more deeply interrogate the role of the
ALK
F1174L mutation on vascular morphogenesis and architecture,
which may be a major determinant of impaired drug delivery and
a contributing factor to the poor prognosis of children with
ALK
F1174L-mutated MYCN-amplified neuroblastoma. The altered
vascular phenotype may also impact on the response to anti-
vascular therapies, including cediranib, currently being considered
in clinical trials for the treatment of high-risk MYCN-amplified
neuroblastoma [33]. Retrospective analysis of historical patholog-
ical samples for ALK mutations should provide sufficient statistical
power to shed a light on the vascular phenotype of neuroblastoma
associated with ALK amplification, and each of the rare ALK
mutations, including the lethal ALK
F1174L mutation.
Coupled with our recent identification of quantitation of R2*a s
a biomarker of treatment response to cediranib in the Th-MYCN
GEM model [8], the present study reinforces R2* as a biomarker
of vasculogenesis and its response to therapy in these clinically
relevant GEM models. Furthermore, it provides a strong rationale
for the evaluation of intrinsic susceptibility MRI for assessing any
anti-angiogenic effects resulting from successful targeted inhibition
of ALK signalling in ALK
F1174L mutated neuroblastoma, which
could ultimately used for the assessment of second generation
ALK inhibitors [34,35]. To conclude, this study has provided a
strong rationale for the immediate incorporation of intrinsic
susceptibility MRI into forthcoming imaging-embedded clinical
trials of next generation ALK inhibitors in ALK-mutated and -
amplified neuroblastoma.
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